Curis (CRIS) News Today

Truist Financial reaffirmed a "buy" rating and set a $26.00 target price on shares of Curis in a research note on Wednesday.

Curis, Inc. (NASDAQ:CRIS - Free Report) - Equities researchers at HC Wainwright increased their Q2 2024 earnings per share estimates for Curis in a research report issued on Wednesday, May 8th. HC Wainwright analyst E. White now anticipates that the biotechnology company will post earnings of ($2

HC Wainwright restated a "buy" rating and issued a $26.00 price target on shares of Curis in a report on Wednesday.

Curis (NASDAQ:CRIS - Get Free Report) released its earnings results on Tuesday. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.94) by ($0.11). Curis had a negative return on equity of 169.22% and a negative net margin of 473.04%. During the same period last year, the business earned ($2.40) EPS.

Curis (NASDAQ:CRIS) Share Price Crosses Above 200-Day Moving Average of $10.49

Curis, Inc. (NASDAQ:CRIS - Get Free Report) was the recipient of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 47,900 shares, a drop of 14.5% from the February 29th total of 56,000 shares. Approximately 0.8% of the shares of the company are sold short. Based on an average daily trading volume, of 35,000 shares, the days-to-cover ratio is presently 1.4 days.

Citigroup Inc. lowered its holdings in shares of Curis, Inc. (NASDAQ:CRIS - Free Report) by 95.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 91,871 shares of the biotechnology company's stock after sel

Curis (NASDAQ:CRIS) Stock Price Crosses Above 200-Day Moving Average of $10.26

Kingdon Capital Management L.L.C. trimmed its holdings in Curis, Inc. (NASDAQ:CRIS - Free Report) by 87.8% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 309,150 shares of the biotechnology company's stock after selling 2,215,274 shares during

Citigroup Inc. cut its position in Curis, Inc. (NASDAQ:CRIS - Free Report) by 95.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 91,871 shares of the biotechnology company's stock after selling 1,745,553 s

Bleichroeder LP reduced its holdings in Curis, Inc. (NASDAQ:CRIS - Free Report) by 90.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 24,999 shares of the biotechnology company's stock after selling 225,001 shares during the quarter. Bl

Curis (NASDAQ:CRIS - Get Free Report) announced its quarterly earnings results on Thursday. The biotechnology company reported ($2.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.91) by ($0.12). Curis had a negative return on equity of 135.38% and a negative net margin of 460.45%. The firm had revenue of $2.70 million for the quarter, compared to analysts' expectations of $2.95 million. During the same period last year, the company posted ($2.40) earnings per share.